Hui Ping Wu

Direttore/Membro del Consiglio presso XinYu Pharmaceutical Co., Ltd.

52 anni

Finance

Health Technology

Profilo

Hui Ping Wu is an Independent Director at XinYu Pharmaceutical Co., Ltd.
since 2016.
Prior to this, Wu was an Independent Director at Shanghai Tongda Venture Capital Co., Ltd.

Posizioni attive di Hui Ping Wu

Società	Posizione	Inizio
XinYu Pharmaceutical Co., Ltd. XinYu Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Xinyu Pharmaceutical Co., Ltd. engages in the research, development, and production of microbial pharmaceuticals. Its key products are the active pharmaceutical ingredient lincomycin hydrochlorlde and its derivatives, which include clindamycin hydrochloride and clindamycin phosphate, as well as neomycin sulphate, moxidectin, framycetin sulphate, tenofovir disoproxil fumarate, nosihepitde premix, and enramycin premix. The company was founded in 1988 and is headquartered in Suzhou, China.	Direttore/Membro del Consiglio	01/12/2016

Tutte le posizioni attive di Hui Ping Wu

Precedenti posizioni note di Hui Ping Wu

Società	Posizione	Fine
SHANGHAI TONGDA VENTURE CAPITAL CO., LTD.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Hui Ping Wu

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Hui Ping Wu

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
SHANGHAI TONGDA VENTURE CAPITAL CO., LTD.	Finance

Aziende private	1
XinYu Pharmaceutical Co., Ltd. XinYu Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Xinyu Pharmaceutical Co., Ltd. engages in the research, development, and production of microbial pharmaceuticals. Its key products are the active pharmaceutical ingredient lincomycin hydrochlorlde and its derivatives, which include clindamycin hydrochloride and clindamycin phosphate, as well as neomycin sulphate, moxidectin, framycetin sulphate, tenofovir disoproxil fumarate, nosihepitde premix, and enramycin premix. The company was founded in 1988 and is headquartered in Suzhou, China.	Health Technology